Supplementary Table from Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR+/HER2− Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1)

Authors :: Stacy Moulder
Das Purkayastha
Hope S. Rugo
Cynthia Ma
Lowell Hart
Sibel Blau
Tara Sanft
Meghan Karuturi
Denise A. Yardley
Amelia Zelnak
Amy S. Clark
Angela DeMichele
Sara A. Hurvitz
Aditya Bardia
Publication Year :: 2023
Publisher :: American Association for Cancer Research (AACR), 2023.
Abstract: Supplementary Tables

Full Text Access

Tools